TallacTherapeutics announces AACR 2021 presentation on preclinical data for TAC-001, the lead program from our novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform. “TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models”